NASDAQ · CTKB
Healthcare · Medical - Devices
$4.61
Up+$0.08 (+1.77%)
Updated Sep 12, 2026, 11:53 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CTKB closed at $4.61 after 20 trading sessions, down 1.71% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $4.61 | $4.64 | $4.485 | $4.61 | 897.71K |
| Sep 10, 2026 | $4.69 | $4.70 | $4.51 | $4.53 | 2.42M |
| Sep 9, 2026 | $4.59 | $4.75 | $4.55 | $4.73 | 810.26K |
| Sep 8, 2026 | $4.64 | $4.68 | $4.54 | $4.62 | 649.72K |
| Sep 4, 2026 | $4.67 | $4.7285 | $4.62 | $4.70 | 478.23K |
| Sep 3, 2026 | $4.70 | $4.77 | $4.515 | $4.70 | 485.32K |
| Sep 2, 2026 | $4.66 | $4.78 | $4.58 | $4.69 | 564.63K |
| Sep 1, 2026 | $4.775 | $4.805 | $4.55 | $4.62 | 629.43K |
| Aug 31, 2026 | $4.63 | $4.805 | $4.48 | $4.78 | 958.63K |
| Aug 28, 2026 | $4.62 | $4.71 | $4.48 | $4.68 | 796.31K |
| Aug 27, 2026 | $4.57 | $4.735 | $4.56 | $4.62 | 651.35K |
| Aug 26, 2026 | $4.53 | $4.58 | $4.509 | $4.57 | 437.7K |
| Aug 25, 2026 | $4.45 | $4.58 | $4.36 | $4.58 | 605.08K |
| Aug 24, 2026 | $4.80 | $4.84 | $4.29 | $4.44 | 943.49K |
| Aug 21, 2026 | $4.69 | $4.83 | $4.59 | $4.81 | 820.26K |
| Aug 20, 2026 | $4.63 | $4.78 | $4.615 | $4.66 | 800.61K |
| Aug 19, 2026 | $4.67 | $4.92 | $4.67 | $4.70 | 1.04M |
| Aug 18, 2026 | $4.77 | $4.77 | $4.60 | $4.67 | 713.32K |
| Aug 17, 2026 | $4.66 | $4.76 | $4.57 | $4.74 | 497.83K |
| Aug 14, 2026 | $4.84 | $4.935 | $4.6614 | $4.69 | 927.48K |
The latest Smart Investors Daily articles mentioning CTKB.
CTKB research
Company profile and research snapshot.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 13, 2026 | Stephens & Co. | Overweight | — |
| May 12, 2026 | Morgan Stanley | Equal-Weight | — |
| Jan 8, 2026 | TD Cowen | Buy | — |
| Nov 11, 2025 | Piper Sandler | Overweight | — |
| May 28, 2025 | Morgan Stanley | Equal-Weight | — |
Generated Sep 11, 2026, 9:14 PM
Cytek Biosciences shares gained 1.77% today, reflecting cautious optimism despite a concerning earnings picture. The company continues to demonstrate strong instrument sales momentum, though mounting losses are raising questions about the path to profitability.
Bottom line: Cytek presents a classic growth-stage biotech hardware story with encouraging top-line momentum but concerning bottom-line deterioration. Investors should closely watch whether management can demonstrate a clear path to profitability within the next 2-4 quarters, as expanding losses offset the encouraging signal from growing instrument sales.
Yahoo · Sep 9, 2026
On August 5, Cytek Biosciences (NASDAQ:CTKB) reported financial results for the second quarter ended June 30, and the report reads like two different companies at once. Revenue climbed, margins widened, and the installed base of instruments kept expanding. At the same time, the net loss more than doubled from a year earlier and adjusted EBITDA […]
Yahoo · Sep 3, 2026
FREMONT, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- As clinical laboratories seek deeper cellular insights, greater efficiency, and more streamlined approaches to cell analysis, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) will showcase its advanced solutions at two leading clinical cytometry events this fall: the European Society for Clinical Cell Analysis (ESCCA) 2026 Conference and ICCS 2026, the 41st Annual International Clinical Cytometry Meeting & Course. Set apart
Yahoo · Sep 1, 2026
FREMONT, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.Wells Fargo 21st Annual Healthcare Conference in Boston, MACFO William McCombe will be participating in investor meetings on Tuesday, September 8, 2026Morgan Stanley 24th Annual Global Healthcare Conference in New York, NYCEO Wenbin Jiang and CFO William McCombe will be partic
Benzinga · Aug 21, 2026
Cytek Biosciences, Inc. ("Cytek Biosciences," "Cytek," or the "Company") (NASDAQ:CTKB), a leading cell analysis solutions company, today announced that a jury in the United States District Court
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CTKB.
